Drug intelligence / Profile preview

ADC 2

Development stage: Preclinical
Lead developer: Hexagon Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ADC 2 is a preclinical antibody-drug conjugate (ADC) being developed by Hexagon Bio for the treatment of solid tumors. The candidate utilizes a novel Protein Translation Inhibitor (PTI) payload, which is designed to disrupt the protein synthesis machinery within target cells to induce apoptosis. While the specific cell-surface antigen targeted by the antibody component remains undisclosed, ADC 2 represents part of Hexagon Bio's strategy to apply its discovery platform to identify and develop unique natural product-derived payloads for oncology applications.

Other names: ADC 2-Hexagon Investments-ADC-Solid TumorsADC2-Hexagon Investments-ADC-Solid TumorsADC-2-Hexagon Investments-ADC-Solid Tumors

Beyond the preview

Go deeper on ADC 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC 2.

Explore the full profile